Pharmacogenomic testing; knowing more, doing better.

J.E. Lunshof; D. Gurwitz

doi:10.1038/clpt.2011.339

Pharmacogenomic testing; knowing more, doing better.

J.E. Lunshof, D. Gurwitz

AIMMS

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappointingly slow even though research on PGx is thriving. A recent survey on the adoption of PGx testing by US physicians suggests that this trend may start changing for the better. 1 Acquiring more knowledge of PGx tests and their clinical significance during graduate and postgraduate education will enable physicians to make better use of the available and upcoming PGx diagnostics in clinical practice. © 2012 american Society for clinical Pharmacology and Therapeutics.

Original language	English
Pages (from-to)	387-389
Journal	Clinical Pharmacology & Therapeutics
Volume	91
DOIs	https://doi.org/10.1038/clpt.2011.339
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/clpt.2011.339

Persistent URL (handle)

Persistent link

Cite this

@article{daa09344064a4594b7d7c65f9277bf95,

title = "Pharmacogenomic testing; knowing more, doing better.",

abstract = "The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappointingly slow even though research on PGx is thriving. A recent survey on the adoption of PGx testing by US physicians suggests that this trend may start changing for the better. 1 Acquiring more knowledge of PGx tests and their clinical significance during graduate and postgraduate education will enable physicians to make better use of the available and upcoming PGx diagnostics in clinical practice. {\textcopyright} 2012 american Society for clinical Pharmacology and Therapeutics.",

author = "J.E. Lunshof and D. Gurwitz",

year = "2012",

doi = "10.1038/clpt.2011.339",

language = "English",

volume = "91",

pages = "387--389",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Pharmacogenomic testing; knowing more, doing better.

AU - Lunshof, J.E.

AU - Gurwitz, D.

PY - 2012

Y1 - 2012

N2 - The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappointingly slow even though research on PGx is thriving. A recent survey on the adoption of PGx testing by US physicians suggests that this trend may start changing for the better. 1 Acquiring more knowledge of PGx tests and their clinical significance during graduate and postgraduate education will enable physicians to make better use of the available and upcoming PGx diagnostics in clinical practice. © 2012 american Society for clinical Pharmacology and Therapeutics.

AB - The clinical uptake of pharmacogenomic (PGx) testing and genotype-based prescribing has been disappointingly slow even though research on PGx is thriving. A recent survey on the adoption of PGx testing by US physicians suggests that this trend may start changing for the better. 1 Acquiring more knowledge of PGx tests and their clinical significance during graduate and postgraduate education will enable physicians to make better use of the available and upcoming PGx diagnostics in clinical practice. © 2012 american Society for clinical Pharmacology and Therapeutics.

U2 - 10.1038/clpt.2011.339

DO - 10.1038/clpt.2011.339

M3 - Article

SN - 0009-9236

VL - 91

SP - 387

EP - 389

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

ER -

Pharmacogenomic testing; knowing more, doing better.

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this